BrightSpring Health Services, Inc. (NASDAQ: BTSG) — A Pass-Through Pharmacy Roll-Up Priced for Perfection as KKR Heads for the Exit

Independent fundamental research. Report date: 2026-07-03. Data as of the 2026-07-02 close ($69.03). All financials reconcile to SEC filings (FY2025 10-K filed 2026-02-27; Q1’26 10-Q filed 2026-05-01) and the Q1’26 earnings call (2026-05-01). The analysis below carries no investment recommendation and no price target; the single, deliberately-labeled exception is the Claude's Take block.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows carries no recommendation and no price target.

Verdict: HOLD / AVOID adding here — a good-momentum, questionable-quality business that has re-rated to perfection. Not a short. Constructive re-entry zone ≈ mid-$40s to low-$50s (~12–14x forward EV/adjusted-EBITDA — roughly where it traded one quarter ago); at $69 (~18–19x forward, ~24x on FY25 adj-EBITDA, and the richest P/S & P/B in its short public life) there is no margin of safety. Conviction: medium.

BrightSpring is a genuinely large, essential-service healthcare platform with one real growth engine — limited-distribution specialty and infusion pharmacy — bolted onto a low-margin drug pass-through, a mature long-term-care pharmacy, and a smaller but higher-margin home-health/hospice book. The bull narrative (GAAP-profit inflection, ~30% adjusted-EBITDA growth, a clean post-divestiture story, de-leveraging to ~2.3x, and a CMS enrollment moratorium that protects incumbents) is real and coherent, which is why the Street is unanimously positive and the stock is up ~214% in a year. But the tape is the tell: this is a crowded, idiosyncratic momentum re-rate (factor R² ~0.23 — ~77% stock-specific; loading Consumer-Discretionary, not defensive-healthcare) at the richest-ever multiple, on a business earning a ~5% ROIC that does not clear its cost of capital, with negative tangible equity (–$1.08B), ~3x leverage, and a headline “adjusted EBITDA” running ~35% above GAAP on add-backs (SBC, “deal costs”) that never actually go away. The single loudest signal is insider behavior: the best-informed holder — control sponsor KKR (with Walgreens) — is selling as fast as registration windows allow, into the strength, at a rising price ladder ($41 → $58 and higher), while the company spends its thin, levered balance sheet buying stock to absorb the supply. That is exit facilitation, not value-accretive capital return.

The framing is quality-questionable momentum darling, priced for flawless execution, with negatively-skewed risk. You are not being paid to add at $69: the upside needs the compounder story to keep validating perfectly and the multiple to hold at a peak, while the downside needs only one ordinary wobble — a CMS rate action, a DOJ/False-Claims settlement (PharMerica has a $100M + $31.5M history in exactly these verticals), or specialty growth decelerating below ~15% — to compress earnings and the multiple at once on 3.6% margins. Trigger to turn bullish: a pullback into the entry zone or clear evidence ROIC is climbing toward/through WACC as mix shifts to Provider Services and fee-for-service, with the adjusted-to-GAAP gap narrowing. Trigger to turn outright bearish (avoid/lean-short): a material reimbursement cut or DOJ action landing on the thin-margin, levered base, or specialty growth breaking. Tag: “Priced for perfection while the sponsor heads for the exit.”

📈 Stock Price Action — Five-Year Event Map

BrightSpring has only traded publicly for ~2.4 years, and in that span it has gone one direction. The stock IPO’d on 2024-01-26 priced at $13 — below its marketed $15–18 range — and closed its first day at $11; within seven weeks it bottomed at an all-time-low $8.23 close ($7.85 intraday, 2024-03-15), roughly -40% below the IPO. From there it re-rated almost without interruption to an all-time-high $69.85 close (2026-07-01; $70.91 intraday, 2026-07-02) and sits at $69.03 today — ~-1.2% off its high, near the top of a 52-week range of $19.01–$70.91 and up ~+527% from the IPO close (~+750% off the $8.23 low). (Prices: FACT, from public price history. Drivers below: INTERPRETATION.)

Cycle narrative. (1) The stock broke its IPO price on day one and drifted to $8.23 by mid-March 2024 — a soft debut for a highly-levered, KKR/Walgreens-sponsored issuer. (2) A string of quarterly beats and specialty-pharmacy growth turned the tape; the Q3’24 print drove a +15.2% day (11/1/24). (3) The January-2025 agreement to sell the Community Living/I/DD business to Sevita (~$835M; 8-K 1/21/25) was a +12.6% de-levering catalyst, partly given back on the Q4’24 print. (4) The Q1’25 report (8-K 5/2/25) produced the single largest up-day, +16.6%. (5) KKR’s June-2025 secondary was the clearest supply shock — a ~-11% offering week — the recurring cost of a sponsor unwinding a large stake. (6) Through late 2025 the re-rate resumed on continued beats and the FY25 GAAP-profit inflection, with the divestiture closing 3/30/26. (7) The final parabolic leg to the ATH ran on the Q1’26 print (+9.6%, 5/1/26), a term-loan repricing, and a wave of Street initiations — and even a second KKR secondary (8-K 6/5/26; -5.7% on ~15M shares) was absorbed within days. (Each move FACT; each attributed driver INTERPRETATION, traceable to the cited 8-K / print / news item.)

1. Executive Summary

BrightSpring Health Services is a Louisville, Kentucky home-and-community healthcare platform that combines a large pharmacy operation with a smaller, higher-margin provider-services business, serving medically-complex “Senior and Specialty” populations across all 50 states. It was assembled by KKR (with Walgreens Boots Alliance as minority sponsor) from the 2019 combination of PharMerica (long-term-care pharmacy) and ResCare (provider services) and IPO’d in January 2024. FY2025 continuing-operations revenue was $12.91B (+28%), split Pharmacy Solutions $11.4B (88.7%, +30.7%) and Provider Services $1.5B (11.3%, +11.1%).

The central analytical fact is a mismatch between size and economics. Roughly 88% of revenue is drug-cost pass-through booked gross, so consolidated gross margin is just 11.8% and has compressed 500 bps in four years (18.6% FY21 → 11.8% FY25) as the low-margin specialty/Part D mix has grown. GAAP EBITDA margin is 3.6%; company-defined adjusted EBITDA margin ~4.8% (FY25) / 5.3% (Q1’26). ROIC is ~5.0% — below any plausible WACC — because a ~2–3% operating margin sits on top of a $3.07B goodwill-and-intangibles base; the balance sheet carries negative tangible equity (~–$1.08B, –$6.01/share) and ~3x leverage (2.27x post-divestiture). FY25 GAAP net income of $190.7M is flattered by a +$84.3M one-time discontinued-operations gain on the Community Living sale; continuing-ops diluted EPS was $0.48. Free cash flow is real but thin (~$395M FY25, ~3% yield on market cap) and lumpy.

The business has genuine strengths: a legitimate limited-distribution specialty/infusion pharmacy franchise (153 LDDs) growing ~36% with rising gross-profit-per-script; a higher-margin (~16% segment EBITDA) Provider Services book benefiting from a CMS moratorium that freezes new home-health/hospice competitors; a clean two-segment story after divesting the I/DD group-home business to Sevita for ~$835M; de-leveraging from divestiture proceeds; and disciplined, mostly tuck-in M&A (including the Amedisys/LHC home-health assets UnitedHealth was forced to divest). The 2026 guide is revenue $14.7–15.2B and adjusted EBITDA $795–825M (+29–34%).

But the stock has run +214% in a year to the richest P/S and P/B in its history (99th own-percentile), and on the current price the valuation is demanding: at ~$15.0B EV (basic) / ~$16.9B diluted, BrightSpring trades at ~18–19x forward EV/adjusted-EBITDA and ~24x on FY25 adjusted-EBITDA — above the premium home-care roll-ups (ENSG, PNTG) that earn roughly double the margin. The “0.77x sales, so it’s cheap” framing is an artifact of pass-through gross-up and should be discarded. The two structural risks the momentum narrative discounts — a tightening reimbursement/CMS-and-IRA vector, and intense DOJ/False-Claims enforcement in exactly BrightSpring’s verticals (PharMerica has a $100M + $31.5M settlement history) — arrive precisely as control sponsor KKR sells aggressively into the strength and the company repurchases stock to absorb the supply. The business is improving; the price leaves little room for the risks it simultaneously raises.

2. Business Overview

What BrightSpring is. BrightSpring Health Services is a Louisville, Kentucky–based “home and community” healthcare platform that does two very different things under one roof: it runs a large pharmacy operation and a smaller provider-services (in-home clinical and supportive care) operation, both aimed at the same medically-complex “Senior and Specialty” populations. The company traces to the 2019 combination of PharMerica (institutional / long-term-care pharmacy) and ResCare (provider services) under KKR ownership, with Walgreens Boots Alliance as a minority sponsor; it IPO’d in January 2024 (NASDAQ: BTSG). (FACT — FY2025 10-K, Item 1.) The scale is genuinely large: operations in all 50 states, roughly 465,000 patients served at any one time (about 330,000 of them in their homes), ~10,500 clinical providers and pharmacists, some 7,700 office/clinic/customer locations, and roughly 23,500 full-time-equivalent employees (about 3,500 unionized). In 2025 the platform filled over 43 million prescriptions from more than 175 pharmacies, infusion centers and specialty-oncology sites, and delivered ~21 million hours of provider care. (FACT — FY2025 10-K, Item 1.)

Segment one: Pharmacy Solutions — the revenue, not the profit. Pharmacy Solutions generated $11,445.8M of revenue in FY2025 — 88.7% of the total — up 30.7% year-on-year, but only $543.5M of segment EBITDA, a 4.75% segment margin (up from $394.7M in FY24). (FACT — 10-K MD&A and segment note.) It has two sub-lines:

• Infusion & Specialty Pharmacy — home- and clinic-administered infused/injectable/oral therapies for oncology, MS, hemophilia, auto-immune, rare/orphan and other complex conditions. This is the growth engine: prescriptions grew ~27% December-2024-to-December-2025. Its differentiator is access to limited-distribution drugs (LDDs) — 149 live oncology LDDs at year-end (plus 18 to launch; 4 exclusive and 16 “ultra-narrow”), rising to 153 by Q1 2026. Management frames a large tailwind: ~$90B of oncology-drug revenue expected by 2032 from not-yet-launched drugs, plus 415 Phase-III therapies in the pipeline. (FACT — 10-K Item 1; Q1’26 call, 2026-05-01. Pipeline figures are management’s; treat the demand pull as a hypothesis.)
• Home & Community (long-term-care / institutional) Pharmacy — “white-glove,” multiple-times-daily dispensing to senior-living communities, behavioral group homes, skilled-nursing/rehab facilities and hospice patients, within ~100-mile radius of a physical pharmacy. This line is mature: scripts grew only ~3%, and revenue is now declining — Q1’26 revenue of $527M, down 9% year-on-year, driven by an ~$50M Inflation Reduction Act (IRA) reimbursement hit and deliberate exit of uneconomic customers. (FACT — Q1’26 call.)

Why huge revenue, tiny margin — the pass-through mechanic. Pharmacy revenue is inflated by drug acquisition cost. When BrightSpring dispenses a specialty oncology drug or a high-cost Part D medication, the full drug price flows through revenue while the economic spread the company keeps is a thin dispensing/service margin. That is why consolidated gross margin is only 11.8% and has fallen steadily as the low-margin specialty/Part D mix has grown: 17.5% (FY22) → 14.8% (FY23) → 12.6% (FY24) → 11.8% (FY25). (FACT — ROIC profitability ratios.) The practical implication, developed in the relevant section, is that EV/Sales (~0.77x) is meaningless here — the correct lenses are EV/gross-profit and EV/EBITDA. (INTERPRETATION.)

Segment two: Provider Services — small revenue, the real margin. Provider Services generated $1,464.8M of revenue (11.3% of total, +11.1%) but $232.7M of segment EBITDA — a ~15.9% segment margin, more than three times pharmacy’s. (FACT — 10-K MD&A / segment note.) It comprises home health (census +9%), hospice, rehab therapy (hours +12%, including neuro/ABI/TBI and ABA/autism therapy), personal care (activities-of-daily-living support), and a build-out of home-based primary care (directly-employed physicians in certain states, the vehicle for value-based-care contracts). Post-divestiture it serves ~16,000 patients. The strategic logic management sells is integration — the same complex patient buys both pharmacy and provider services, generating longitudinal data and cross-referral. (FACT/INTERPRETATION — 10-K Item 1.)

The single most important structural fact for valuation: Provider Services is only 11% of revenue but ~30% of segment EBITDA. (INTERPRETATION — derived from segment disclosures.) A large corporate overhead sits on top — $318.0M of unallocated SG&A consumes ~41% of the $776.2M total segment EBITDA, bridging down to consolidated GAAP EBITDA of roughly $459.5M. (FACT — 10-K segment note.)

Payor mix — a government rate-taker. Consolidated FY2025 revenue by payor: Medicare Part D 31.7%, Commercial insurance 25.6%, Medicare Advantage (Part C) 18.7%, Medicaid 11.6%, Medicare Part A 8.4%, Part B 0.6%, Private & other 3.4%. That is ~71% government-reimbursed (Medicare A/B/C/D + Medicaid). (FACT — 10-K Note 3.) Concentration is genuinely low — no payor exceeds 35% of revenue, the top-10 Medicaid states are only ~6% of revenue, and no single customer is 10% or more. (FACT — 10-K Note 3.) Diversification is a real risk-mitigant; the flip side is that BrightSpring is a price-taker across nearly three-quarters of its book, with reimbursement set by CMS, state Medicaid agencies and PBMs (Caremark, Optum, ESI, Humana).

Recurring vs. non-recurring. The revenue is overwhelmingly recurring: pharmacy patients average ~9 medications at a time and provider patients average ~6 chronic conditions, and “the vast majority receive services on a recurring basis over long periods.” (FACT — 10-K Item 1.) This is a business of chronic, sticky, daily-need demand — attractive in duration and volume, unattractive in the margin the reimbursement system permits it to keep.

Recent portfolio reshaping. In 2025 BrightSpring divested its Community Living (I/DD group-home) business to Sevita (National Mentor Holdings) for $835M (closed 30 March 2026; ~$811M net cash proceeds before tax), reclassifying it to discontinued operations and restating history. (FACT — 10-K Item 1; 8-K 2026-03-31; Q1’26 call.) The stated rationale — sharper focus, a “refined payor mix,” and higher growth in home health/rehab/primary care/hospice — is examined in the relevant section; for the overview, it leaves a cleaner two-segment story: a pass-through pharmacy engine plus a higher-margin, smaller provider business.

3. Industry Dynamics

BrightSpring straddles three distinct industries. They share favorable demographics — the “Senior and Specialty” chronic-care population is large and growing, which the company sizes at a >$2.0 trillion total spend pool — but they differ sharply in structure and profitability. (FACT — 10-K Item 1; the $2T figure is management’s TAM framing, not a served market.)

(a) Specialty & home-infusion pharmacy — best growth, thin economics, deep-pocketed competitors. The U.S. infusion market is roughly $100B, with home infusion ~$13B, and specialty pharmacy is growing structurally on the drug pipeline (Option Care investor materials; management’s ~$90B-by-2032 oncology figure). (FACT — Option Care Health investor materials, accessed 2026-07-03.) The demand tailwind is real: an aging population, a wave of high-cost biologics and oncology agents, and a payer preference for lower-cost home/alternate sites over hospital administration. But the profit structure is poor. Reimbursement for Part-B-administered and Part-D specialty drugs is largely cost-plus-a-thin-fee; the market is fragmented with no dominant player, and the largest and best-capitalized competitors — Optum Infusion, Coram/CVS, Accredo (Cigna) — are vertically-integrated payors that can steer their own members. Option Care Health, the largest independent, does ~$5.65B of infusion revenue at low-teens EBITDA margins. Volume growth is attractive; pricing power is not. (FACT/INTERPRETATION.) A specific overhang: Medicare’s home-infusion benefit remains constrained by the Cures Act structure, which management is actively lobbying to fix. (FACT — Q1’26 call.)

(b) Long-term-care / institutional pharmacy — mature, consolidating, under reimbursement reset. This is a slower-growth, scale-driven business serving skilled-nursing, senior-living and group-home facilities. Structure at the top is effectively a duopoly-plus-roll-up: BrightSpring’s PharMerica and CVS’s Omnicare have historically been the two national leaders — but CVS has been winding Omnicare down, and Guardian Pharmacy Services (FY25 revenue ~$1.33–1.35B, growing 15–20%) is aggressively rolling up independents. (FACT — company filings, accessed 2026-07-03.) The reimbursement backdrop is deteriorating: DIR-fee reform (moving pharmacy price concessions to point-of-sale, effective 2024) already reset margins, and the IRA Part D redesign — the $2,000 (2025)/$2,100 (2026) out-of-pocket cap, elimination of the coverage-gap phase, a shift of catastrophic liability onto plans, and the first 10 CMS-negotiated drug prices effective January 2026 — is a direct headwind. BrightSpring quantifies the hit to its Home & Community pharmacy at ~$50M in Q1’26 and ~$45M per remaining 2026 quarter (~$175M for the year). (FACT — Q1’26 call; KFF, Drug Channels, accessed 2026-07-03.) Structurally, this is a mediocre industry: sticky facility relationships and scale purchasing, but pass-through economics and a policy environment actively compressing the margin.

© Home health & hospice — demographic tailwind, budget-neutral rate regime, and a newly-raised entry barrier. Demand is strong (aging in place, lower-cost-than-facility care), but Medicare sets the price and has spent years extracting it back. Home health runs under the Patient-Driven Groupings Model (PDGM) since 2020, with CMS clawing back “budget-neutrality” adjustments through CY2026; the CY2025 HH PPS update was a net +2.7%. Hospice got a +2.6% FFY2026 update but is constrained by the aggregate cap ($35,361.44 for FFY26) and the 20% inpatient cap. (FACT — 10-K Item 1.) The most consequential recent development is the CMS six-month nationwide enrollment moratorium on new Home Health Agencies and Hospices, announced 13 May 2026 under the Vance-led anti-fraud task force (QSO-26-11). It bars initial enrollments and non-exempt changes in majority ownership, leaves existing providers untouched, and is extendable in six-month increments. (FACT — AHA News 2026-05-13; CMS newsroom; law-firm alerts, accessed 2026-07-03.) The moratorium is incumbent-protective — it freezes new competitive capacity and makes an existing Medicare billing number scarcer/more valuable — but it cuts both ways for BrightSpring: it also freezes non-exempt acquisitions of existing agencies, partially constraining the company’s own tuck-in M&A unless structured to qualify as exempt. (INTERPRETATION.) The segment remains fragmented and consolidating: UnitedHealth/Optum is absorbing Amedisys (~$3.3B) and LHC; Chemed’s VITAS is the largest hospice (~$1.6B, ADC >22,000); Addus (~$1.5B), Pennant (2026 guide $1.13–1.17B) and Enhabit (~$1.0B) are the other public comparables. (FACT — 8-Ks, Hospice News, accessed 2026-07-03.)

Verdict — structurally mixed, tilting unattractive. In Greenwald/Marathon terms, these are industries with strong secular volume demand but weak profit-pool economics: ~71% government-reimbursed, rate-taking, pass-through pharmacy, and a chronic labor-cost and staffing constraint (clinicians and pharmacists in short supply). There is no industry-wide pricing power; margins are set by CMS, state Medicaid and PBMs, and the current policy vector (IRA, DIR reform, PDGM clawbacks) is compressing them. The one genuinely favorable structural shift is supply-side — the CMS moratorium temporarily curbs new home-health/hospice entry — but it is narrow, temporary, and does not touch the pharmacy segments where 89% of revenue sits. Net: good demand, bad-to-mediocre profit structure. This is not a structurally attractive industry; it is a volume-growth industry in which returns are policed by the payer.

4. Competitive Position

Does a moat exist, and what type? BrightSpring’s own case rests almost entirely on scale and density. In Greenwald’s taxonomy that is an economies-of-scale advantage — which is only durable when paired with customer captivity. BrightSpring layers on two secondary elements: intangibles (its 153 limited-distribution and exclusive/ultra-narrow oncology drugs, and manufacturer/GPO relationships) and modest switching costs (daily multiple-times-a-day facility pharmacy service inside a ~100-mile radius, EMR/eMAR integration, and the “white-glove” service model that facilities are reluctant to disrupt). (INTERPRETATION — 10-K Item 1.) The scale is real and not merely rhetorical: BrightSpring is one of the two national leaders in LTC pharmacy (alongside CVS’s Omnicare, which is being wound down), a top independent in specialty/infusion, and a national multi-state provider-services operator — a footprint few can replicate. That scale yields genuine advantages in drug purchasing, route density, payer contracting, LDD access and fixed-cost absorption, all of which the company cites and which are plausible. (FACT/INTERPRETATION.)

But the moat does not show up where it must — in returns on capital. This is the crux, and it is damning. FY2025 ROIC is ~5.0% — below any plausible weighted cost of capital for a levered healthcare-services company — and gross margin is not just thin but falling (17.5%→14.8%→12.6%→11.8% over FY22–25). (FACT — ROIC profitability ratios.) A durable moat is supposed to manifest as pricing power, stable-or-rising margins, and excess returns on invested capital. BrightSpring shows the opposite pattern: rising revenue, compressing gross margin, and sub-cost-of-capital ROIC. The scale is being competed away into the reimbursement system rather than retained by shareholders. The tell is unambiguous — this is scale without pricing power. (INTERPRETATION.) The heavy $318M corporate overhead (41% of segment EBITDA) compounds the point: whatever scale economies exist in the field are substantially consumed before they reach the consolidated line.

Pressure-testing switching costs and intangibles. The switching costs are modest, not deep. Facility pharmacy relationships are sticky day-to-day but are contract-based and periodically re-competed; LTC pharmacy contracts change hands regularly (indeed, BrightSpring itself is exiting “uneconomic” customers). The LDD exclusivity is a real but borrowed advantage — the drug is exclusive because the manufacturer chose BrightSpring’s network, a decision the manufacturer can revisit; it is not an owned barrier. The integration/“complementary pharmacy + provider” thesis is intuitively appealing and generates cross-referral, but there is little evidence it produces excess returns rather than simply more low-margin volume — and value-based-care contracting remains early. (INTERPRETATION; OPEN QUESTION — the financial payoff of integration is asserted by management, not yet demonstrated in segment economics.)

Head-to-head vs. named competitors.

• Infusion/specialty: Option Care Health (OPCH) is the larger independent (~$5.65B infusion revenue, 315k patients) and BrightSpring’s infusion sub-segment is smaller; more importantly, Optum Specialty/Infusion, Coram/CVS and Accredo (Cigna) are vertically-integrated payors that can direct their own members — a structural disadvantage BrightSpring cannot out-scale. (FACT.)
• LTC pharmacy: peer to Omnicare/CVS at the top, but Guardian Pharmacy (~$1.33–1.35B, +15–20%) is growing far faster off a roll-up model, and the whole category faces the IRA/DIR margin reset. BrightSpring’s national scale here is real but is a share leader in a shrinking-margin pond. (FACT/INTERPRETATION.)
• Home health / hospice / personal care: a fragmented field — UnitedHealth/Optum (Amedisys + LHC), Chemed/VITAS (largest hospice, ~$1.6B), Addus (~$1.5B), Pennant, Enhabit — where BrightSpring is one competitor among many, none dominant, and the deepest-pocketed entrant is a payer-owned platform. (FACT.)

Verdict — real scale, weak moat; a crowded, low-margin roll-up. BrightSpring has assembled a legitimately large, hard-to-replicate national footprint, and it enjoys narrow, genuine advantages (LDD access, facility density, purchasing). But a moat must be tied to a financial outcome that would deteriorate without it — and here the financial outcome is already poor: ~5% ROIC, sub-WACC, on a falling gross margin, in industries where ~71% of revenue is priced by the government and the largest competitors are integrated payers. The scale mitigates risk (diversification, no >35% payor, no >10% customer) more than it creates excess returns. This is best characterized as a defensible market position without a durable competitive advantage — a low-margin healthcare-services roll-up whose “moat” does not, on the evidence, convert into returns on capital. The bull case must rest on operating leverage, mix-shift toward Provider Services, and continued volume growth — not on pricing power that the returns show it does not have.

5. Growth History and Forward Opportunities

BrightSpring’s headline growth is arresting and, on the top line, largely illusory as a measure of value creation. Continuing-operations revenue (ex the divested Community Living I/DD business) rose from $7.69B (2023) → $10.07B (2024, +31%) → $12.91B (2025, +28%) — a two-year near-doubling that has powered the stock’s ~214% one-year move. But roughly 88% of that revenue sits in Pharmacy Solutions, a drug-cost pass-through business carrying a low-double-digit gross margin (FY25 consolidated gross margin ~11.8%). The correct lens for a distribution-heavy model is not revenue dollars but gross-profit dollars and EBITDA — and there the story is genuinely better than the top line, which is the crux of the growth-quality question. (Fact/Interpretation)

Segment decomposition — where the growth actually comes from. In FY25, Pharmacy Solutions grew +30.7% to $11.4B and Provider Services +11.1% to $1.5B. The Q1’26 print sharpens the picture with sub-segment detail:

(All figures Fact, BTSG Q1’26 call, 5/1/26; drivers Interpretation.)

The engine is unambiguously Specialty & Infusion Pharmacy, growing ~36% on ~30% specialty-script growth (infusion mid-teens). This is a genuine limited-distribution-drug (LDD) franchise: BrightSpring carried 153 LDDs at Q1’26 (added 4 exclusive ultra-narrow nodes in the quarter; 5 LDD wins in six months), and management claims rising drug-by-drug share because exclusive/ultra-narrow networks mechanically deliver 50–100% share of a given molecule. Layered on top is a fee-for-service “hub”/data-services business (31 hub programs, growing 40–50%/yr) that carries high gross margin and deepens manufacturer relationships. (Fact/Interpretation)

Is this high- or low-quality growth? The tell is in the divergence between revenue and profit growth. Q1’26 revenue grew +26% but adjusted EBITDA grew +45% (margin 5.3%, +70 bps), and gross profit per specialty script rose ~50% YoY. The company’s own 2026 guidance encodes the same divergence: revenue +14–18% but adjusted EBITDA +29–34%. That gap is the evidence that the growth is not merely thin-margin pass-through inflation — it reflects favorable mix (specialty/infusion, brand-to-generic conversion where BrightSpring keeps more of the spread), scale procurement, and fee-for-service. Management itself cautions that the ~50% GP/script step-up is not repeatable (“stability there would be very good”), so the profit-growth rate should decelerate toward the volume rate. Verdict: the revenue line is low-quality (pass-through, sub-3% operating margin, ROIC ~5% below WACC — see the relevant section); but the gross-profit-dollar and EBITDA growth is legitimately higher-quality than the top line implies. The honest characterization is a thin-margin distribution business improving its mix and monetization, not a structurally high-return compounder. (Interpretation)

Home & Community (LTC) Pharmacy is the drag — down 9% in Q1’26 on a ~$175M FY26 IRA revenue headwind plus deliberate exits of uneconomic contracts. Notably, ex-IRA, that segment’s profit was up YoY, so the revenue decline overstates the economic hit; script growth ex-exits was mid-single-digit. This is a mature, competitive LTC-pharmacy business (legacy PharMerica) with limited organic growth, run for margin and cash. (Fact/Interpretation)

Provider Services growth is roughly half acquired (Amedisys/LHC branches contributed +$79M of the +$96M Home Health increase in Q1’26) and half organic census/de novo. Home Health’s underlying quality metrics are strong (>91% of branches ≥4 stars, >99% timely initiation of care), which supports market-share gains and preferred Medicare Advantage contracting. Rehab and Personal Care grow at low-to-mid single digits — steady but not needle-moving. (Fact)

Forward opportunity and guidance. For 2026, management guides revenue $14.725–15.225B (Pharmacy $12.85–13.3B; Provider $1.875–1.925B) and adjusted EBITDA $795–825M (+29–34%), including ~$30M from the acquired Amedisys/LHC assets, with a full-year margin of 5.2–5.6% and ~$500M operating cash flow. The structural tailwinds are real and durable: (1) aging demographics and the secular shift of acute care into the home/community; (2) a specialty-drug pipeline feeding continuous new-LDD and brand-to-generic conversion cycles; (3) home-infusion white space — BrightSpring covers only ~⅓ of the country on acute infusion and ~½ on chronic, with a multi-year focus building the chronic/LDD side; and (4) early-stage cross-sell/value-based care (home-based primary care, ACO applications) that is optionality, not a current earnings driver. Verdict on growth quality: mixed-to-favorable — high absolute growth of modest-quality economics, with the profit mix improving. The bull must underwrite continued LDD wins and margin capture; the bear notes that ~half of Provider growth is bought, the top line is pass-through, and the ~50% GP/script jump is explicitly non-recurring. (Fact/Interpretation/Assumption)

6. Financial Quality

Verdict up front: BrightSpring is a low-margin, working-capital-light, debt-funded healthcare aggregator whose reported “quality” rests almost entirely on a self-defined Adjusted EBITDA that runs ~35% above GAAP EBITDA. Cash generation is real but thin relative to a $12.9B revenue base; returns on the all-in (goodwill-laden) capital base do not clear the cost of capital. Economics improve only marginally with scale — SG&A leverages, but gross margin is compressing faster than operating leverage builds.

The revenue engine: growth is real, but low-quality drug pass-through

Continuing-operations revenue has compounded from $5.58B (FY2020) to $12.91B (FY2025) — roughly 18% annualized — but the mix has migrated decisively toward the lowest-margin activity in the portfolio. (FACT, ROIC/10-K.)

The 500-basis-point gross-margin compression from FY21 to FY25 is the single most important number on the income statement. It is not a cost problem; it is a mix outcome. Pharmacy Solutions grew revenue +30.7% (+$2.7B) in FY25 to $11.4B and now represents ~88% of the top line, but it carries a 4.8% segment EBITDA margin ($543M). Specialty and infusion pharmacy is essentially a drug-cost-plus distribution business: BrightSpring buys expensive branded/specialty molecules and dispenses them at a thin spread. Every incremental dollar of specialty drug revenue dilutes the consolidated gross margin even as it grows gross-profit dollars. (FACT, 10-K MD&A + segment note.)

Provider Services is the genuinely higher-quality half: $1.5B revenue (+11.1%) at a ~15.9% segment EBITDA margin ($232M), roughly 3x Pharmacy’s margin. But it is one-eighth the size and growing half as fast. The structural tension is that the fast-growing segment is the low-quality one, and the high-quality segment is the slow-growing one. Consolidated adjusted EBITDA margin was just 4.8% in FY25 (5.3% in Q1’26) — this is a razor-thin-margin business where a 100-bp reimbursement or drug-mix shock would swing EBITDA by ~$130M. (INTERPRETATION.)

GAAP vs. Adjusted EBITDA: how “adjusted” is it?

Management steers on Adjusted EBITDA and Adjusted EPS; those are also the metrics its bonus plan pays on (above). The FY25 bridge (continuing operations) is the crux of the quality question:

The add-backs equal +34.8% of GAAP EBITDA — a large wedge that deserves scrutiny line by line (INTERPRETATION):

• Share-based comp ($59M) is a real, recurring, dilutive cost. Adding it back is standard practice but analytically generous: SBC is ~15% of FY25 FCF and drives ~2–3% annual share-count creep. It is compensation, not a one-time item.
• Acquisition/integration/transaction costs ($40M) recur every year because BrightSpring is a serial acquirer by design. For a permanent roll-up, “deal costs” are an ordinary operating expense, not a non-recurring adjustment. FY24 carried $32M of the same.
• Restructuring/divestiture ($60M) includes ~$23M of Community Living separation costs — legitimately tied to a discrete event — but the balance is ongoing “cost-savings” restructuring that has appeared for years.

The cleaner reads — legal settlements (~$22M) and KKR management fees (~$23M) — were FY24 items that rolled off (post-IPO the monitoring agreement was terminated), which flatters the FY24→FY25 adjusted comparison. A skeptic normalizing for recurring SBC and deal costs would put “true” cash EBITDA closer to ~$520–560M than $617.6M — roughly $60–100M below the headline. Adjusted EPS of $1.00 (vs. $0.48 GAAP diluted) embeds the same add-backs plus a tax-adjustment credit. Treat the $618M as a promotional number and the ~$460M GAAP EBITDA as the conservative floor; the truth is in between.

The FY25 GAAP net income is flattered by a one-time gain — strip it

FY25 GAAP net income of $190.7M includes a +$84.3M discontinued-operations gain on the Community Living sale (FACT). Continuing-operations net income was $104.8M and continuing diluted EPS was $0.48 — the number that matters for run-rate. Anyone anchoring on the $0.87 GAAP diluted EPS or the ~$191M net income is capitalizing a divestiture gain. Q1’26 repeats the pattern: $148.8M GAAP net income includes a further $74.3M disc-ops item, versus $0.34 continuing diluted EPS. (FACT.)

Working capital and cash conversion: the one genuinely attractive feature

Because the pharmacy is a pass-through funded substantially by trade payables, the business runs a short, improving cash-conversion cycle: ~16 days in FY25 (DSO ~27, DIO ~23, DPO ~34), down from ~30 days in FY22 (FACT, ROIC working-capital ratios). Capex is light at $95M (~0.7% of revenue). This is why FY25 CFO of $490M dwarfed continuing NI of $105M and FCF reached $394.7M. The caveat: growth still consumes working capital in bursts — FY24 CFO collapsed to $23.8M on a $270M WC drag, and FY22 CFO was negative. Cash flow is genuine but lumpy and inventory/receivable-sensitive; a single quarter of specialty-drug inventory build can erase a quarter of FCF. (INTERPRETATION.)

Leverage, coverage, and negative tangible equity

BrightSpring carries $2.70B of total debt (First Lien Tranche B-5 term loan of ~$2,553M at SOFR+~2.5%, ~6.8–7.0% cash cost, plus leases). On the company’s own Adjusted EBITDA, net leverage fell from ~3.9x at 12/31/25 to ~2.3x at 3/31/26 — but that deleveraging was achieved almost entirely by parking the ~$811M of Community Living cash proceeds on the balance sheet, not by repaying principal (total debt was flat quarter-over-quarter). A meaningful slice of that cash is spoken for: cash taxes on the gain (~$100M) are payable in Q2’26, so “true” net leverage is modestly higher than the headline. (FACT/INTERPRETATION.)

Interest coverage is thin but improving: Adjusted EBITDA/interest ~3.9x, GAAP EBITDA/interest ~2.9x, EBIT/interest just ~1.9x. Interest expense of $157M consumes ~34% of GAAP EBITDA. The debt is floating-rate (interest-rate risk) and the term loan runs to 2031. (FACT, ROIC credit ratios.)

The balance sheet’s defining feature is negative tangible equity of roughly –$1.08B (Q1’26): $2.53B goodwill + $0.54B intangibles exceed total equity of $1.99B. Tangible book value per share is –$6.01; the tangible-common-equity ratio is –34%. This is the accounting signature of a debt-funded roll-up that has paid up for acquired businesses — the equity value is entirely goodwill and future cash flows, with no asset backstop. (FACT.)

Returns on capital: below the cost of capital

FY25 ROIC (return on invested capital) is ~5.0% and ROA ~3.1% (FACT). Against a plausible WACC of ~8.5–9.5% (floating-rate debt at ~7% pre-tax, equity cost ~10–11%), the business is not earning its cost of capital on a GAAP basis. Even adjusting NOPAT for the non-cash add-backs lifts ROIC only to roughly ~7–8% — still short. The reason is structural: the denominator includes $2.53B of goodwill accumulated buying ResCare/PharMerica/Abode and dozens of tuck-ins, and the numerator is a ~2–3% operating margin. Incremental operating margin was 6.6% in FY25 and management touts SG&A leverage “in all 20 quarters” — there is genuine, if modest, operating leverage — but gross-margin compression from mix is running ahead of it. (INTERPRETATION.)

Verdict: Financial quality is below average. The growth is real but structurally low-margin and increasingly concentrated in pass-through specialty pharmacy; the headline Adjusted EBITDA/EPS are inflated ~35%/2x over GAAP by add-backs that substantially recur; GAAP net income is flattered by a one-time divestiture gain; the balance sheet shows negative tangible equity and floating-rate leverage; and all-in ROIC sits below WACC. The two redeeming features — a short cash-conversion cycle and demonstrated SG&A leverage — are real but not enough to call this a high-quality compounder. Economics improve with scale only at the margin.

7. Capital Allocation

Verdict up front: capital allocation is dominated by two things — an aggressive, debt-funded M&A roll-up, and the machinery of a controlling-sponsor exit. Management has deleveraged opportunistically and bought a genuinely strategic home-health asset, but it is also spending a thin, levered balance sheet to repurchase stock at ever-rising prices specifically to absorb KKR’s selling. That is facilitation, not value-accretive capital return. No dividend; no open-market insider buying; incentives keyed to a self-defined EBITDA.

Use of IPO and divestiture proceeds. The January 2024 IPO (common stock + 6.75% Tangible Equity Units) raised $1,045M net, which went to deleveraging: repayment of the entire Second Lien Facility plus $343M of First Lien term loan (FACT, 10-K). This was sensible — pre-IPO leverage exceeded 8x. Since the IPO the company has repriced/refinanced the first lien twice (Tranche B-4 in 2024, Tranche B-5 in 2025) to shave spread as leverage fell — competent liability management. The Community Living divestiture (I/DD group homes, HCBS waiver programs, ICFs) sold to Sevita/National Mentor for $835M gross / ~$811M net cash, closing 30 March 2026 (FACT, 8-K/transcript). This was a clean portfolio decision: exit a lower-growth, labor-intensive, reimbursement-exposed business and redeploy toward the pharmacy/home-health core. The proceeds sit in cash pending Q2’26 tax payment; management has signaled “additional flexibility” — some combination of M&A, debt paydown, and buyback still to be decided. The deployment of the ~$811M is the single most important near-term capital-allocation decision and is not yet resolved. (OPEN QUESTION.)

M&A cadence: a permanent roll-up. BrightSpring is, structurally, an acquisition machine. FY25 deployed ~$205M of cash on tuck-in acquisitions, and the company acquired the Amedisys/LHC home-health and hospice locations (107 locations, ~$239M) that Optum/UnitedHealth was forced to divest for antitrust clearance. That asset is already material — +$79M revenue and +$9M adjusted EBITDA in Q1’26 alone, with ~$30M of adjusted EBITDA expected in FY26 (FACT, transcript). Management explicitly frames scale in Provider Services as “the most important determinant of sustainability,” so more M&A is coming, stated to stay “within that target leverage range.” R&D is de minimis. (INTERPRETATION.)

Buybacks: absorbing the sponsor’s exit, not returning value. There is no dividend. The “buybacks” that have occurred are not opportunistic value-return — they are concurrent repurchases tied to KKR/Walgreens secondary offerings. In the October 2025 secondary the company repurchased 1.5M shares ($43M); it announced a further ~$60M buyback alongside the March 2026 20M-share secondary, and repurchased again in the June 2026 secondary (FACT, 10-K/8-K). Critically, these repurchases occur at a rising price ladder — roughly $28 (Oct’25) → $41 (Mar’26) → $58 (Jun’26) — i.e., the company is spending its levered, thin-FCF balance sheet to buy its own stock at successively higher momentum prices, with the explicit function of soaking up sponsor supply. Repurchasing shares of a negative-tangible-equity business at ~18x current-year and ~24x FY25 EV/Adjusted-EBITDA, while ROIC sits below WACC, is difficult to defend on intrinsic-value grounds. This is exit facilitation dressed as capital return. (INTERPRETATION — a genuine red flag.)

The Tangible Equity Units and dilution. The 6.75% TEUs (BTSGU) are $1,000 units comprising a prepaid stock purchase contract plus a senior amortizing note due 1 February 2027; the purchase contracts mandatorily settle into common around February 2027. The share impact is largely captured in the diluted share count (FY25 diluted 219.8M vs. basic 202.6M), so “surprise” dilution at settlement is limited, but basic shares will step up at settlement. Overall share count has risen from 171M (FY23) to ~193M outstanding / ~221M diluted (Q1’26) — driven by the IPO primary issuance, TEU dilution and ~2–3%/yr SBC creep, only partially offset by the small concurrent buybacks. Net direction is still up. (FACT/INTERPRETATION.)

Incentive alignment. The 2026 proxy ties the annual incentive to Adjusted EBITDA — the very metric management defines and adjusts — supplemented by quality/growth measures; long-term equity is PSUs and options. Legacy 2017-plan performance options vest on 5-year adjusted-EBITDA targets and on KKR achieving a specified return — sponsor-return-linked rather than public-shareholder-TSR-linked (FACT, 10-K/DEF 14A). Alignment is therefore medium: paying management on a self-defined, adjustment-heavy EBITDA rewards the same add-backs that inflate the headline.

SEC Sweep & Insider Signal

Corpus reviewed: 3× 10-K, 7× 10-Q, 32× 8-K, 3× DEF 14A/DEFA14A, 20× Form 3, 83× Form 4 (plus S-1/S-3ASR/424B7 shelf machinery). Insider signal — an unambiguous one-way sell: there have been zero open-market purchases (code P) by any insider since the IPO. The Form 4 corpus is entirely (a) IPO-time Form 3 initial-ownership statements, (b) disposition (code S) filings tied to registered secondaries by KKR, Walgreens and management, and © routine equity-comp mechanics — grants (A), option exercises (M), and tax-withholding forfeitures (F). KKR is exiting rapidly and continuously at rising prices: Jun’25 (~16.1M sh) → Oct’25 → Mar’26 20.0M sh @ ~$41 → Jun’26 ~15.0M sh @ ~$58 — the stake falling from majority at IPO to ~21.8% (post-Mar’26) to ~13.7% (post-Jun’26); Walgreens is also exiting. The 8-K timeline confirms the Q1’26 cash build was the Community Living sale close (3/30/26, ~$811M net), not a refinancing or equity raise. One-time items to normalize: the +$84.3M FY25 disc-ops gain (and +$74.3M in Q1’26). Net read: the best-informed holder — the control sponsor that has run this company since 2019 — is selling as fast as registration windows allow, into a +200% move, while the company deploys cash to help clear the supply, and no insider is buying. That is a bearish tell on valuation, independent of the operating story.

8. Changes and Headwinds — Last Two Years

The last 24 months reshaped BrightSpring’s portfolio, balance sheet, and shareholder register — mostly in a direction the market has rewarded, but with policy and legal overhangs the momentum tape is discounting.

1) Community Living divestiture (closed 3/30/26) — the defining portfolio move. BrightSpring sold its I/DD group-home business (“Community Living,” legacy ResCare) to Sevita for $835M gross / ~$811M net cash pre-tax (~$100M cash taxes due Q2’26), reported as discontinued operations since Q1’25. The rationale is coherent: I/DD group homes are labor-intensive, lower-growth, and strategically orthogonal to the pharmacy + home-based-clinical thesis. The transaction sharpens the mix and deleveraged the balance sheet materially — net leverage fell from ~3.9x (12/31/25) to ~2.3x (3/31/26). The FY25 GAAP net income flattered by an $84.3M disc-ops gain is a one-time item to normalize out (above). Interpretation: thesis-strengthening — a cleaner, more cash-generative, lower-leverage business.

2) Amedisys/LHC home-health acquisition — buying into a fragmented tailwind. BrightSpring acquired 107 home-health & hospice locations from UnitedHealth for ~$239M — assets UNH was forced to divest as an antitrust remedy for its own Amedisys deal (closed 2025). The assets carry ~$345M pro-forma revenue and are guided to ~$30M year-1 EBITDA. Early integration is running ahead of plan (+$79M revenue, +$9M EBITDA in Q1’26). This is classic BrightSpring: disciplined, mostly-tuck-in M&A extending geographic density. Interpretation: thesis-supportive if integration and hospice/home-health rates hold — but it deepens exposure to precisely the segments now under federal fraud scrutiny.

3) IRA / Part D redesign & policy headwinds — large on revenue, small on profit. 2026 carries ~$600M of gross revenue headwind: IRA in Home & Community (~$175M), IRA in Specialty & Infusion (~$181M), and brand-to-generic conversions (~$250M). Critically, management quantifies the net adjusted-EBITDA drag at only ~$15M — the headwind is overwhelmingly a top-line, low-margin phenomenon being mitigated by procurement and operational offsets. DIR-fee reform (point-of-sale, effective 2024) is a cash-timing rather than margin event. Interpretation: real but well-telegraphed and largely absorbed — not thesis-breaking, but a reminder that this is a regulated, reimbursement-exposed model with limited pricing power. (Fact/Interpretation)

4) CMS home-health/hospice enrollment moratorium (5/13/26) — double-edged. CMS imposed a six-month nationwide pause on NEW home-health and hospice Medicare enrollments under the Anti-Fraud Task Force, targeting “systemic and deeply troubling fraud.” For an incumbent the moratorium is near-term protective — it freezes new competitor entry. But it is also a flare: the federal government is actively hunting fraud in the exact segments BrightSpring just paid $239M to expand into. (Fact; both readings Interpretation)

5) DOJ / False Claims Act exposure — structural, with legacy precedent. LTC pharmacy and hospice/home health are among the most DOJ-audit-heavy corners of healthcare, and BrightSpring’s PharMerica subsidiary has a track record: a $100M Anti-Kickback/FCA settlement (Silver qui tam, agreed Nov 2023, court-approved July 2024) over below-cost SNF Part A drug pricing used to win Part D/Medicaid volume, plus a $31.5M Controlled Substances Act/FCA settlement. These are legacy/settled, but they establish that the model repeatedly attracts whistleblower and regulator attention — a persistent tail risk, now amplified by the 2026 fraud crackdown. Interpretation: a standing overhang, not a current crisis, but under-priced by a momentum tape at a record valuation. (Fact/Interpretation)

6) Capital-structure & ownership changes. Post-divestiture deleveraging plus strong cash generation has management “actively evaluating” a further term-loan repricing (interest ~$35M/quarter). On the register, KKR and Walgreens continue steadily selling down: a June 2026 secondary of ~15M shares (KKR + management), following prior secondaries in Jan/Jun 2025 and March 2026, against which BrightSpring repurchased stock (no primary proceeds to the company). The persistent KKR/Walgreens overhang is a technical headwind even as it improves float. (Fact; overhang read Interpretation)

7) GLP-1 / biosimilar / PBM dynamics — low direct exposure. BrightSpring is not a retail dispenser, so GLP-1 pass-through is not a meaningful driver or headwind. On biosimilars and PBM private-label steering, management asserts low near-term exposure because the specialty portfolio is oral-solid oncology and infusible. Open Question: management assertions to validate against future data. (Interpretation/Open Question)

Verdict: On balance the last two years strengthen the thesis operationally — a cleaner, deleveraged, higher-mix business with well-absorbed IRA headwinds, a protective enrollment moratorium, and disciplined accretive M&A. But the same period concentrates the two structural risks the momentum narrative is discounting: intensifying federal fraud enforcement in home-health/hospice/LTC pharmacy (with a proven PharMerica FCA history), and a continuing sponsor stock overhang — arriving precisely as the stock trades at its richest-ever P/S and P/B. The changes improve the business; the price leaves little margin for the risks they simultaneously raise. (Interpretation)

9. Risk Analysis

BrightSpring’s risk profile is dominated by three structural features that compound each other: (a) razor-thin margins that leave no cushion for a reimbursement or cost shock, (b) ~3x leverage on a negative-tangible-equity balance sheet, and © near-total dependence on government-payor policy. A business earning a ~5% ROIC does not have the profit buffer to absorb a 100–200 bp reimbursement cut without visibly impairing EBITDA — and the equity is priced for the opposite. The matrix is ordered roughly by expected severity.

Catastrophic-loss assessment: a total loss is low-probability — this is a cash-generating, going-concern operator with essential-service revenue and a moratorium-protected Provider franchise. But a 50%+ drawdown is a live scenario and requires no exotic trigger: a single adverse CMS rate cycle or a material DOJ settlement, landing on 3.6% margins and 3x leverage, would simultaneously cut EBITDA and collapse the multiple — the classic double-hit that turns a momentum darling into a value trap. The negative tangible equity means there is no book-value floor to catch the fall.

10. Valuation

The single most important valuation point precedes any multiple: for BrightSpring, EV/Sales is not merely uninformative — it is actively misleading, and every “0.77x sales, so it’s cheap” framing is wrong. Roughly 88% of revenue (Pharmacy Solutions) is drug-cost pass-through booked gross; consolidated gross margin is 11.8% and EBITDA margin 3.6% — the economics of a distributor bolted onto a mid-margin services business. The correct lenses are EV/EBITDA, EV/EBIT, EV/gross-profit and free-cash-flow yield — and on those, BrightSpring is not cheap; it is priced at the high end of its peer group and at the richest multiple in its own two-year public history.

A required data correction. Some third-party data feeds still show an enterprise value of ~$10.5B struck at the 3/31/26 period price of $42.61; the stock is now $69.03 (+62%). At the live price the figures are materially higher — and any “forward ~13x, so reasonable” read that leans on the stale EV is wrong. (FACT — reconstructed from 193.2M basic / ~221M diluted shares, net debt $1.61B.)

Against its own history the picture is unambiguous: own-history valuation percentiles put P/S at the 99.4th and P/B at the 99.4th percentile — the richest valuation BrightSpring has ever traded at since its January 2024 IPO (FACT, valuation-percentile data). Read P/B and P/S the way a negative-tangible-equity name demands, and both say richest-ever. Discount the P/E percentile (45.7th) — GAAP EPS is depressed and noisy.

Sector comp table (TTM EV/EBITDA and growth)

(Peer EV/EBITDA from public aggregated data, TTM; peer EVs may also be period-lagged and are directional. BTSG re-struck at the live price.)

Two things fall out. First, on the metrics that matter BrightSpring trades at the top of the group — ~18.5x forward / ~24x FY25 adjusted EV/EBITDA, above every services peer except the two premium roll-ups (ENSG 23.7x, PNTG 23.9x) — and both of those earn roughly double the EBITDA margin and, in ENSG’s case, a far higher ROIC. Second, the two structurally correct margin analogs for the 88%-of-revenue pharmacy pass-through — Cencora (1.6%) and McKesson (1.8%) — trade at 13–16x EBITDA on razor-thin margins, which is exactly the range that should anchor the Pharmacy segment. BrightSpring’s consolidated 3.6% margin sits between a distributor and a services company; its consolidated multiple sits above both cohorts.

The forward number — only palatable if you accept “adjusted”

The bull’s defense is that trailing GAAP EBITDA understates the run-rate. It does. Management guides 2026 adjusted EBITDA of $795–825M (mid $810M), +29–34% over the ~$618M FY25 adjusted base (FACT). But even on that number, at the live EV of ~$15.0B (diluted ~$16.9B), the forward multiple is ~18.5x (diluted ~20.8x) — still a premium, not a bargain. And the reconciliation depends on a ~$159M adjustment bridge (~35% uplift) from FY25 GAAP EBITDA to the adjusted base — SBC, transaction/integration and restructuring. Apply the same haircut to the 2026 guide and forward EV/GAAP-equivalent EBITDA is ~25x. Below the adjusted line sit ~$95M capex, ~$140–157M cash interest, and cash taxes, leaving owner FCF of ~$395M (FY25) — a ~3.0% FCF yield on market cap for a business earning a ~5% ROIC below its WACC.

Sum-of-the-parts (warranted — genuinely different businesses)

Valuing the segments separately on 2026E (ASSUMPTION-heavy — segment adj-EBITDA margins estimated to tie to the $810M consolidated guide):

(ASSUMPTION; multiples from the comp table.) The SOTP midpoint (~$9.9B EV) sits well below the actual ~$15.0B EV (diluted ~$16.9B). Even crediting bull-end multiples on both segments, the parts do not add to the whole at today’s price. The takeaway is decisive: there is no hidden conglomerate discount to unlock — the market is already paying a premium to full segment value. (INTERPRETATION.)

Embedded expectations — what must be true

At today’s ~$15.0B EV, holding a ~13x terminal peer EV/adjusted-EBITDA (generous for a 5%-ROIC business), the market needs roughly $1.15B of adjusted EBITDA to “grow into” the price — about the 2028 run-rate implied by ~30% compounding continuing for two-plus years. So the stock is pricing several more years of near-flawless ~30% adjusted-EBITDA growth and the multiple holding. The bear’s rebuttal is that all three load-bearing assumptions are fragile: (1) that 25–30% adjusted growth persists (it is specialty-volume and M&A-driven, not organic margin expansion); (2) that the ~35% GAAP-to-adjusted bridge is genuinely non-recurring (for a serial acquirer, “deal costs” are permanent); and (3) that reimbursement and DOJ risk stay dormant. Fail any one and the correct anchor snaps back toward a ~14x GAAP-EBITDA multiple on a 5%-ROIC, 3x-levered, negative-tangible-equity balance sheet — the setup for compression, not expansion.

Verdict: BrightSpring is priced for continued flawless execution at the richest valuation in its short public history. On the current price the forward EV/adjusted-EBITDA is ~18.5x — above the premium peers that earn twice the margin — and on GAAP economics the multiple is demanding. The SOTP confirms there is no margin of safety embedded in the price. (No price target; the directional view is fenced in Claude’s Take.)

11. Variant Perception

The consensus. Sell-side is uniformly bullish — Goldman initiated Buy (6/8/26); TD Cowen Buy PT $81 (6/18); BTIG Buy PT $90 (6/22); BofA Buy PT $77 (7/2) — with not a single Hold or Sell visible. The consensus story is clean: (1) a GAAP-profitability inflection; (2) a secular specialty/infusion tailwind with fee-for-service hub programs growing 40–50%; (3) a clean post-divestiture story (Community Living sold, balance sheet de-levered); and (4) a moat-adjacent tailwind — the May 2026 CMS moratorium on new home-health/hospice enrollments is incumbent-protective. Wrap it in a “0.77x sales” headline and a raised guide, and you get a stock up +214% in a year with the entire analyst community cheering it higher.

The strongest bull case. Specialty pharmacy is a genuinely good place to be, and BrightSpring has scale in it. If the specialty/infusion engine keeps compounding 25–40%, mix shifts toward higher-value fee-for-service, Provider Services rides the enrollment moratorium and demographics, and management delivers the $810M adjusted-EBITDA guide, then a ~30% grower with a de-levering balance sheet arguably deserves a premium multiple that holds rather than compresses — and the +214% run is the early innings of a multi-year compounder, with the sponsor sell-down simply liquidity.

The strongest bear case. Strip the narrative and BrightSpring is a low-margin, ROIC-5% roll-up trading at its richest-ever multiple, at the top of a +214% momentum move, with every dollar of profit dependent on tightening government-payor policy. The “0.77x sales” cheapness is an artifact of pass-through gross-up. The GAAP-profit “inflection” is flattered by an $84M one-time gain and rests on a ~35% adjusted-EBITDA add-back bridge that, for a serial acquirer, never goes away. Growth is bought and volume-driven, not margin-expanding — which is why ROIC sits below WACC even as revenue compounds (the Marathon capital-cycle warning: capital pouring into a business that isn’t earning its cost of capital). The balance sheet carries negative tangible equity and 3x leverage, so there is no asset floor. And the KKR/Walgreens overhang guarantees a steady supply of stock into any strength. The bear doesn’t need a catastrophe — just for one of reimbursement, the DOJ, or the growth rate to disappoint, at which point the multiple re-rates hard.

The 3–5 assumptions that matter, and what falsifies each

The factor-positioning read — is consensus offsides? The tape says this is a crowded, idiosyncratic momentum trade, not a discovered value name. A quantitative factor model puts 12-month relative strength at +209.97 (≈+214%), beta 1.10, alpha 0.93, with the stock loading the Consumer-Discretionary sector — an unusual, risk-on signature for a nominally-defensive healthcare-services company. Critically, the model’s R² is only ~0.23: ~77% of the move is idiosyncratic — company-specific narrative and flows, not a factor tide. The nearest factor-similar peers are high-beta ETFs and commodity names (RGLD, TECK, ARKK), not home-health/pharmacy comps — a match on return shape, not business model. That is the empirical fingerprint of a stock priced by story and momentum. This cuts both ways: BTSG is less exposed to a factor-momentum unwind (little factor crowd to exit), but the entire move rests on continued company-specific execution and multiple expansion — now at richest-ever percentiles against a unanimous-Buy Street and a sponsor incentivized to sell. The variant perception is not that the bull story is wrong — specialty pharmacy is real — but that it is fully, richly priced with negative skew: the upside needs the compounder narrative to keep validating flawlessly, while the downside needs only one ordinary policy, legal or growth wobble to collapse both earnings and multiple at once.

Verdict: The consensus is directionally reasonable on the business and dangerously complacent on the price and the risk asymmetry. The evidence points to a crowded, momentum-driven long at a peak multiple on below-WACC economics — a setup where being “right on the company” and “wrong on the trade” can easily coincide.

12. Fact vs. Interpretation Table

13. Open Questions

1. Use of the ~$811M Community Living proceeds — debt paydown (shareholder-friendly) vs. more exit-facilitation buybacks vs. M&A? The single most important near-term capital-allocation signal.
2. Durability of the ~50% gross-profit-per-specialty-script step-up — management calls it non-recurring; how fast does profit growth decelerate toward volume growth?
3. Any active DOJ/FCA investigation at BTSG (vs. the settled PharMerica legacy matters) — verify against 10-K legal proceedings and future 8-Ks.
4. Segment adjusted-EBITDA margins are not cleanly disclosed — the SOTP relies on estimates; better segment profitability disclosure would sharpen the valuation.
5. How much of the ~35% adjusted add-back actually recurs across a full cycle — the crux of whether ~18.5x forward is really ~18.5x or closer to ~25x on cash economics.
6. Terminal specialty-pharmacy margin — does mix-shift and fee-for-service lift consolidated margin structurally, or does reimbursement claw it back?
7. KKR/Walgreens residual timeline — how many more secondaries until the overhang clears, and at what pace?

14. What Must Be True

Bull case — for the stock to compound from here, ALL must hold:

1. Specialty/infusion + fee-for-service keeps compounding 25–40%, richening mix; falsification test: specialty script growth decelerates below ~15%, or gross-profit-per-script reverts, in any two consecutive quarters.
2. Adjusted EBITDA is a fair proxy for cash economics and ROIC climbs toward/through WACC; falsification test: owner-FCF and GAAP EBITDA keep lagging adjusted by ~30%+ and ROIC stays below ~8% through 2027.
3. Reimbursement stays broadly stable (no material PDGM/hospice/Part D cut) and no DOJ/FCA action lands; falsification test: a CMS rate action or a material DOJ settlement in any core vertical.
4. The premium multiple holds as the sponsor exits; falsification test: the multiple mean-reverts toward peer 11–14x on a growth or macro wobble.

Bear case — for the stock to de-rate sharply, ANY ONE suffices:

1. A reimbursement cut lands on 3.6% margins and 3x leverage → EBITDA miss + multiple compression together; falsification test (of the bear): BTSG absorbs a real CMS/IRA cut with flat-to-up EBITDA (as it did the ~$600M IRA gross headwind for ~$15M net).
2. A DOJ/FCA settlement in home health, hospice or pharmacy; falsification test: the enforcement wave passes BTSG by over the next 12–18 months.
3. Specialty growth proves access-dependent (an LDD/hub loss); falsification test: BTSG keeps adding net LDDs and hub programs while holding share.
4. The multiple simply mean-reverts as momentum breaks and KKR keeps selling; falsification test: the stock holds its premium through the remaining sponsor sell-down.

15. Source Appendix

See Appendix B for the full, categorized source list. Primary sources: BrightSpring FY2025 Form 10-K (filed 2026-02-27); Q1’26 Form 10-Q (filed 2026-05-01); Q1’26 earnings call transcript (2026-05-01); 8-K material events (Community Living close 2026-03-31; secondary offerings 2025–26); DEF 14A. Quantitative cross-checks: public aggregated financial data (statements, ratios, enterprise value, valuation multiples), EDGAR XBRL, price history and valuation percentiles, factor-model positioning. Industry/policy: CMS newsroom and QSO-26-11 (2026-05-13 moratorium); KFF and Drug Channels (IRA Part D redesign); Option Care Health, Chemed, Addus, Pennant, Enhabit, Guardian Pharmacy public filings. All non-obvious facts are dated and cited.

APPENDIX A — Standard Diligence Questionnaire

BrightSpring Health Services, Inc. (NASDAQ: BTSG) — as of 2026-07-03

Supplemental to the memo. Fact / Interpretation / Assumption labels where they matter.

General

What thoughtful questions have other investors asked about this company? The recurring debates: (1) Is the ~30% adjusted-EBITDA growth durable or is it specialty-drug-volume pass-through plus M&A? (2) How “real” is adjusted EBITDA given the ~35% add-back bridge and a serial-acquirer deal-cost stream? (3) Does the ROIC (~5%) ever clear WACC, or is capital being poured into a below-cost-of-capital roll-up (Marathon’s warning)? (4) How much does the IRA/Part D redesign actually cost on the bottom line (answer: ~$15M net on ~$600M gross)? (5) How long does the KKR/Walgreens overhang last, and is the company’s stock buyback prudent or just exit-facilitation? (6) Is the valuation (richest-ever P/S & P/B) defensible for a 3.6%-margin, government-reimbursed business?

Cyclicality & Earnings Nature

Cyclical high or low? Neither cyclical in the industrial sense — demand is chronic-care, demographically-driven and non-discretionary. But earnings are at a structural inflection high: GAAP just turned positive (flattered by a one-time gain), adjusted EBITDA margin is expanding (4.8%→5.2–5.6% guided), and the growth rate (~30%) is elevated by specialty-drug launches and M&A that management itself flags as partly non-repeatable (the ~50% GP/script jump). (Interpretation) External environment or internal actions? Both — internal (mix-shift to specialty/FFS, SG&A leverage, portfolio pruning) and external (specialty-drug pipeline, aging demographics, CMS moratorium). Reimbursement policy (external) is the dominant swing factor. How stable are revenues? Very stable in volume (recurring, sticky, ~9 meds/patient), but the dollar level is sensitive to drug-cost pass-through and reimbursement resets. Outlook: 2026 revenue guide $14.7–15.2B, adjusted EBITDA $795–825M. How big will this market be? Management sizes a >$2T Senior & Specialty spend pool (TAM framing, not served market); the served specialty/infusion and home-health markets are large and growing mid-to-high single digits structurally. Domestic (100% US).

Business Quality & Competitive Moat

More or less competitive? Specialty/infusion is fragmenting under deep-pocketed payer-owned entrants (Optum, CVS, Cigna); LTC pharmacy is consolidating (Guardian rolling up, Omnicare winding down); home health/hospice is fragmented and consolidating (UNH/Optum absorbing Amedisys). Net: intensely competitive, with the best-capitalized competitors being integrated payers. How profitable is the business? Low: gross margin 11.8%, EBITDA margin 3.6%, ROIC ~5.0% (below WACC), ROE distorted by negative tangible equity. Provider Services (~16% segment EBITDA margin) is 3x more profitable than Pharmacy (~4.8%). How profitable is the industry / barriers to entry? Mediocre profit pools; barriers are scale/density and (for home health/hospice) Medicare certification — temporarily raised by the CMS moratorium. Pharmacy barriers are LDD manufacturer relationships (borrowed, not owned). Easily understood? Yes at the segment level; the consolidated financials are obscured by pass-through gross-up and heavy adjustments. Undermined by foreign low-cost labor? No — care is delivered locally, in-home/in-facility; labor risk is domestic clinician/pharmacist availability and wage inflation. Do brands matter? Modestly — facility/payer relationships and clinical quality scores matter more than consumer brand. Nature of competition / switching costs? Contract-based, periodically re-competed; day-to-day stickiness (daily dispensing, eMAR integration) but modest, not deep switching costs.

Financial Condition & Balance Sheet

Assets not on the balance sheet? The LDD/manufacturer relationships and payer contracts are valuable but unrecognized; conversely, goodwill/intangibles ($3.07B) exceed equity. Off-balance-sheet liabilities? Operating/finance leases are on-balance-sheet (~$202M capital leases); watch contingent legal/FCA exposure (PharMerica history) and the ~$100M Q2’26 cash-tax liability on the divestiture gain. How conservative is the accounting? Aggressive on presentation — heavy adjusted-EBITDA add-backs (~35%), a one-time gain lifting GAAP NI. Revenue recognition (implicit price concessions on government/pharmacy billing) requires estimation. (Interpretation) How CapEx-hungry? Light — capex ~0.7% of revenue (~$95M). The capital intensity is in working capital (specialty-drug inventory + receivables) and M&A, not fixed assets.

Capital Allocation & Management

FCF generation & use / philosophy? FY25 FCF ~$395M; used for M&A tuck-ins, deleveraging, and stock repurchases tied to sponsor secondaries. Philosophy is roll-up-and-integrate, with opportunistic liability management. Significant acquisitions recently? Yes — the Amedisys/LHC home-health assets (107 locations, ~$239M, DOJ-required UNH divestiture) plus ~$205M of FY25 tuck-ins. Serial acquirer by design. Buying back shares? Yes, but concurrent with KKR/Walgreens secondaries at rising prices ($28→$41→$58) — functionally exit-facilitation, not opportunistic value return. (Interpretation — red flag.) Issuing shares to insiders? SBC ~$59M/yr (~2–3% dilution); overall share count up (171M→~193M/~221M diluted). No open-market insider buying. Compensation policy / motivations? Annual incentive keyed to self-defined Adjusted EBITDA; legacy performance options vest partly on KKR achieving a target return — sponsor-aligned more than public-TSR-aligned. Management’s dominant motivation is currently enabling the sponsor’s monetization. (Interpretation)

Valuation & Market Data

ADR / MLP / K-1? No — US C-corp common stock (plus 6.75% Tangible Equity Units, BTSGU, converting ~Feb 2027). No K-1. Dividend policy? None. How profitable / net income vs. cash flow? GAAP net income diverges from continuing economics (flattered by disc-ops gain); CFO ($490M FY25) exceeds continuing NI ($105M) due to pass-through working-capital funding and D&A — but CFO is lumpy (collapsed to $24M in FY24 on WC build).

Risks & Downside

What would cause the stock to decline? A CMS/IRA reimbursement cut; a DOJ/FCA settlement; specialty-growth deceleration; a growth or margin miss triggering multiple compression from a peak; continued sponsor supply; rate-driven interest-cost pressure on floating debt. Catastrophic loss risk? A 50%+ drawdown is a live, low-trigger scenario (thin margins × leverage × peak multiple). Total loss is low-probability — essential-service, cash-generative, going concern — but negative tangible equity means no book-value floor. Chance of total loss? Low.

Recent News & Events

Has the environment changed recently? Yes: Community Living divested (closed 3/30/26); Amedisys/LHC assets acquired; IRA Part D redesign phasing in; CMS enrollment moratorium (5/13/26); a wave of sell-side Buy initiations (Jun–Jul 2026); continued KKR/Walgreens secondaries. Significant acquisitions/divestitures? Both (above). Accounting-policy change? Community Living reclassified to discontinued operations (history restated). New markets/facilities/management? Geographic tuck-ins; leadership change minimal (the Community Living president left with the divested business).

APPENDIX B — Source Appendix

BrightSpring Health Services, Inc. (NASDAQ: BTSG) — accessed 2026-07-03

Primary — SEC filings (EDGAR, CIK 0001865782)

• FY2025 Form 10-K (filed 2026-02-27, btsg-20251231.htm) — Item 1 Business; MD&A; Notes 3 (revenue/payor), 17 (segments); adjusted-EBITDA reconciliation; debt (First Lien Tranche B-5); legal proceedings. https://www.sec.gov/Archives/edgar/data/1865782/000119312526079454/btsg-20251231.htm
• Q1’26 Form 10-Q (filed 2026-05-01, btsg-20260331.htm) — balance sheet (cash $889M, net debt $1.61B), continuing EPS $0.34, disc-ops. https://www.sec.gov/Archives/edgar/data/1865782/000119312526199339/btsg-20260331.htm
• FY2024 10-K (2025-03-06) and FY2023 10-K (2024-03-06) — multi-year trend, restated for discontinued ops.
• 8-K 2026-03-31 (btsg-20260330) — Item 2.01 completion of Community Living sale to National Mentor Holdings (Sevita).
• 8-Ks 2025–2026 — quarterly earnings; secondary offerings (424B7) Oct 2025, Mar 2026 (~$41), Jun 2026 (~$58); term-loan repricings.
• DEF 14A (2025/2026) — incentive metrics (Adjusted EBITDA), legacy KKR-return-linked performance options.
• S-1 / S-3ASR / 424B7 — IPO (Jan 2024, common + 6.75% Tangible Equity Units) and selling-stockholder secondaries.
• Form 3/4 corpus (20 Form 3, 83 Form 4) — insider/sponsor transactions: zero code-P open-market buys; KKR/Walgreens code-S dispositions via secondaries.

Primary — company IR / earnings

• Q1’26 earnings call transcript (2026-05-01) — 2026 guidance (revenue $14.725–15.225B; adjusted EBITDA $795–825M; margin 5.2–5.6%; leverage 2.27x; ~$500M OCF; ~$35M/qtr interest); segment/LDD detail; IRA ~$15M net drag. Company IR: https://ir.brightspringhealth.com
• Q1’26 press release / guidance — https://ir.brightspringhealth.com (news releases, 5/1/26).

Quantitative cross-checks (public data — reconciled to filings)

• Aggregated financial data — income statement, balance sheet, cash flow (FY21–FY25 + Q1’26); profitability/credit/working-capital ratios (ROIC ~5.0%, ROA ~3.1%); enterprise value & valuation multiples (note: one feed’s EV was struck at the 3/31/26 price $42.61 — re-struck at live $69.03).
• EDGAR XBRL — authoritative concept-level cross-check for US filer.
• Public price history — full since-IPO OHLCV, moving averages, beta/alpha; five-year event map.
• Own-history valuation percentiles — P/S 99.4th, P/B 99.4th, P/E 45.7th, composite 81.5th.
• News flow — recent-events timeline; sell-side initiations (Goldman 6/8/26; TD Cowen $81 6/18; BTIG $90 6/22; BofA $77 7/2).
• Factor model — loadings (Market ~0.93, Consumer-Discretionary ~0.35, Liquidity −0.39; R² ~0.23), leaderboard (rs_12m +209.97, y1 Sharpe 5.33, max DD −12.5%), related-stocks (RGLD/TECK/ARKK — return-shape, not comps).

Industry / policy

• CMS newsroom / QSO-26-11 — 2026-05-13 six-month moratorium on new home-health & hospice Medicare enrollments; AHA News (2026-05-13); law-firm client alerts.
• CMS — CY2025 HH PPS (PDGM) rule; FFY2026 hospice update & aggregate cap ($35,361.44).
• KFF / Drug Channels — IRA Part D redesign ($2,100 OOP cap 2026; first 10 negotiated prices effective Jan 2026); DIR-fee reform.
• Comparable-company filings — Option Care Health (OPCH), Amedisys (AMED), Enhabit (EHAB), Addus (ADUS), Pennant (PNTG), Chemed/VITAS (CHE), Ensign (ENSG), Guardian Pharmacy, Cencora (COR), McKesson (MCK) — comp EV/EBITDA, margins, growth.
• DOJ / press — PharMerica $100M AKS/FCA settlement (Silver qui tam, 2023/2024); $31.5M Controlled Substances Act settlement.

All non-obvious facts are dated and cited; management commentary is treated as a hypothesis and validated against filings and external data.